Table 3.
Management and treatment administered in kidney transplant recipients with COVID-19.
| Parameters | Number | Percentage |
|---|---|---|
| Treatment parameters | ||
| Hospitalization | 41 | 61.2 |
| Domiciliary | 26 | 38.8 |
| Room air management | 33 | 49.3 |
| Oxygen with mask | 16 | 22.9 |
| Noninvasive ventilator | 5 | 7.5 |
| Ventilator | 14 | 20.9 |
| Steroid | 67 | 100 |
| Azithromycin | 29 | 43.3 |
| HCQS | 5 | 7.5 |
| Ivermectin | 39 | 58.2 |
| Doxycycline | 37 | 55.2 |
| Tocilizumab | 7 | 10.4 |
| Remdesivir | 23 | 34.3 |
| Convalescent plasma | 22 | 32.8 |
|
| ||
| Thromboprophylaxis | ||
| Anti-platelet | 2 | 3 |
| LMWH | 31 | 45.3 |
| OAC | 18 | 26.9 |
|
| ||
| Anti-nucleoside drugs | ||
| Continued | 10 | 14.9 |
| Dose reduced | 3 | 4.5 |
| Drug stopped | 51 | 76.1 |
| Not taking | 3 | 4.5 |
|
| ||
| CNI drugs (tacrolimus or cyclosporine) | ||
| CNI continued | 48 | 71.6 |
| CNI dose reduced | 1 | 1.5 |
| CNI stopped | 18 | 26.9 |
|
| ||
| Need for dialysis support (CRRT/SLEDD) | ||
| AKI patients needing dialysis∗ | 13 | 20.6 |
|
| ||
| Computerized tomographic scanning with CT score (N = 30) | ||
| CT score <10 | 09 | 30 |
| CT score 11–14 | 06 | 20 |
| CT score ≥15 | 15 | 50 |
| ICU requirement | 19 | 28.4 |
| Antibiotics used | 41 | 61.2 |
| Anti-fungal used | 18 | 26.9 |
HCQS, hydroxy chloroquine sulphate, LMWH, low molecular weight heparin, OAC, oral anti-coagulants, and CNI, calcineurin inhibitors. ∗Patients with advanced graft dysfunction planned/initiated on HD during pandemic before PCR positivity were excluded.